Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
NCT03934840Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, cabazitaxel ginsenoside liposome injection, abiraterone in prostate cancer (PCa), sponsored by Masonic Cancer Center. Started Oct 2019; status: completed.
02
Drugs
carboplatincabazitaxel ginsenoside liposome injectionabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03934840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934840.